Cathepsin B Study: New Clues in Liver Disease Research

A growing body of evidence points to the gut as a critical battleground in liver disease — and a newly published study may have identified one of the key molecular weapons responsible for the damage. Research published in the Journal of Hepatology (Fondevila et al., 2026) suggests that an enzyme called cathepsin B, produced by immune cells in the intestine, may play a central role in breaking down the gut's protective barrier and accelerating the progression of alcohol-associated liver disease (ALD). The findings could open a new therapeutic avenue for a condition that currently has very few effective treatment options.

What This Study Found

The research team analyzed fecal proteomic data — essentially a detailed inventory of proteins found in stool samples — from two independent multicenter patient cohorts. The first cohort (InTeam) included 80 patients with alcohol-associated hepatitis (AH), 20 patients with alcohol use disorder (AUD), and 19 healthy controls. A second cohort (AlcHepNet) included 80 AH patients, 20 AUD patients, and 18 controls.

Researchers found that levels of cathepsin B — a protease, or protein-degrading enzyme — were progressively elevated as disease severity increased, rising from healthy controls to patients with AUD and reaching their highest levels in patients with AH. Critically, elevated fecal cathepsin B activity was also associated with higher short-term mortality in AH patients, suggesting it may serve as a clinically relevant biomarker.

To investigate causality, the team turned to preclinical mouse models. Mice genetically engineered to lack cathepsin B in myeloid cells (immune cells including macrophages) showed a stabilized intestinal barrier when subjected to an alcohol-feeding protocol. Oral treatment with CA074 — a gut-restricted cathepsin B inhibitor, meaning it acts locally in the intestine without systemic absorption — produced similar results: preserved levels of the tight junction protein occludin, reduced bacterial endotoxin (lipopolysaccharide) in the bloodstream, and attenuated liver inflammation and fat accumulation (steatohepatitis).

The study further revealed the molecular mechanism: cathepsin B, predominantly expressed in intestinal macrophages and upregulated by ethanol exposure, directly cleaves occludin — a structural protein that helps seal the gaps between intestinal epithelial cells. When occludin is degraded, the gut lining becomes permeable, allowing bacteria and their toxic byproducts to migrate to the liver, triggering inflammation and injury. Enzymatic assays, molecular modeling, and peptide profiling confirmed specific cathepsin B cleavage sites on the extracellular region of occludin.

In a particularly compelling set of experiments, transgenic mice engineered to overexpress occludin in their intestinal epithelial cells were largely protected from ethanol-induced liver damage — and the protective effects of the cathepsin B inhibitor CA074 were blunted in these animals, strongly supporting the idea that occludin degradation is the primary mechanism through which cathepsin B drives disease.

Clinical Significance

Alcohol-associated hepatitis is one of the most severe and rapidly progressive forms of liver disease. In its most serious presentations, liver transplantation remains the only reliably effective intervention — yet transplantation is available to only a limited subset of patients, due to stringent eligibility criteria, organ availability, and ongoing alcohol use concerns. Medical therapies for AH have shown modest and inconsistent benefit at best, underscoring the urgent need for novel treatment targets.

This study is notable for several reasons. First, it bridges human observational data with mechanistic animal studies, establishing a plausible causal pathway rather than a mere association. Second, it identifies a specific, druggable molecular target — cathepsin B — that operates locally in the gut. Because CA074 is gut-restricted, the researchers suggest it could potentially inhibit cathepsin B activity in the intestine without causing systemic side effects, a meaningful consideration for patients who may already have compromised organ function.

Third, the identification of fecal cathepsin B activity as a potential biomarker associated with short-term mortality may have diagnostic and prognostic implications. If validated in future clinical studies, cathepsin B measurements in stool could help clinicians identify patients at highest risk and prioritize them for more aggressive intervention.

It is important to note that while the human cohort data are compelling, the mechanistic experiments were conducted in mouse models and laboratory-based cell systems (intestinal organoids and epithelial monolayers). Human clinical trials will be necessary to determine whether cathepsin B inhibition is safe and effective in patients with AH or AUD.

Current Access and Compliance Context

At present, cathepsin B inhibitors such as CA074 are not approved for clinical use in humans. The compound used in this study was employed as a research tool to validate the mechanism in preclinical models. No peptide-based or small-molecule cathepsin B inhibitors are currently available as approved therapies for alcohol-associated liver disease or gut barrier dysfunction.

The study does, however, fit within a broader and growing research landscape focused on the gut-liver axis — the bidirectional communication pathway between intestinal health and liver function. Researchers and clinicians increasingly recognize that interventions targeting gut permeability, the microbiome, and intestinal immune activity may represent viable strategies for managing chronic liver diseases. Cathepsin B inhibition represents a promising, mechanistically grounded candidate within this paradigm.

For patients currently managing AUD or liver disease, it is essential to follow evidence-based treatment protocols under the supervision of a qualified healthcare provider. No dietary supplement, peptide compound, or over-the-counter product should be interpreted as a substitute for medical evaluation and care.

What Patients Should Know

If you or someone you care for has been diagnosed with alcohol use disorder, alcohol-associated hepatitis, or chronic liver disease, this research offers reason for cautious optimism — but also a reminder that the science is still developing. Here is what the current evidence suggests:

• The gut matters for liver health. The study reinforces that intestinal barrier integrity is not a peripheral concern — it may be a central driver of liver disease progression. Protecting the gut lining could be as important as directly targeting the liver.
• Immune cells in the gut may be part of the problem. Macrophages, which are immune cells normally tasked with protecting the body, appear to contribute to barrier breakdown in the context of alcohol exposure by releasing cathepsin B. This nuanced understanding could help researchers develop more targeted therapies.
• A potential biomarker may be on the horizon. Fecal cathepsin B activity could eventually help doctors assess disease severity and mortality risk more precisely — though this requires validation in larger, prospective clinical studies before becoming standard practice.
• New therapies are not yet available. While the findings are scientifically exciting, cathepsin B inhibitors have not been approved for human use in this context. Patients should not attempt to self-treat based on these findings.

Discussing emerging research with a knowledgeable physician is always the appropriate first step. A doctor who stays current with advances in hepatology, gastroenterology, and peptide science can help you understand what the evidence means for your individual situation.

Conclusion

The study by Fondevila and colleagues represents a meaningful scientific advance in understanding how alcohol damages the liver through the gut. By identifying cathepsin B as a macrophage-derived enzyme that degrades the tight junction protein occludin — and demonstrating that blocking this enzyme protects the gut barrier and reduces liver injury in preclinical models — the researchers have proposed a compelling new therapeutic target for one of medicine's most challenging conditions.

As research in the gut-liver axis continues to accelerate, staying informed and working with clinicians who understand these emerging pathways becomes increasingly important. To find a qualified healthcare provider who is knowledgeable about the latest research in peptide science and metabolic health, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice. The content presented here is based on a published research study and should not be used as a basis for self-diagnosis or self-treatment. Always consult a qualified and licensed healthcare professional before making any decisions regarding your health, medications, or treatment plans. The Peptide Association does not endorse any specific treatment, drug, or therapy discussed in this article.

---

Citation (AMA Format): Fondevila MF, Kreimeyer H, Hsu CL, et al. Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease. J Hepatol. 2026;(published online ahead of print). doi:10.1016/j.jhep.2026.01.013. PMID: 41654223.